Onyx Takeover May Intensify Interest in Oncology Drug Companies

by Andrew Berens, MD & Thomas Smith, Bloomberg Industries

 

Amgen’s $10.4 billion purchase of Onyx demonstrates an appetite among biotech and pharma for companies with commercialized products and an oncology pipeline. Other oncology-focused biotechs with at least one commercialized product include Incyte, Seattle Genetics, Medivation and Ariad, each with a market value of $3 billion to $6 billion.

 

Read more >>>

Bloomberg BRIEF Newsletters